William J Jagust

List of Publications by Year
in descending order

348 papers	60,578 citations	1704 104 h-index	1116 231 g-index
374 all docs	374 docs citations	374 times ranked	34494 citing authors

#	Article	IF	Citations
1	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.8	7,498
2	NIA–AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.8	5,861
3	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	10.2	3,792
4	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	10.2	3,378
5	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.1	1,216
6	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
7	Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). , 2005, 1, 55-66.		925
8	PET Imaging of Tau Deposition in the Aging Human Brain. Neuron, 2016, 89, 971-982.	8.1	899
9	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain, 2016, 139, 1551-1567.	7.6	833
10	Positron Emission Tomography in Evaluation of Dementia. JAMA - Journal of the American Medical Association, 2001, 286, 2120.	7.4	803
11	Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging, 2011, 32, 1207-1218.	3.1	611
12	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia, 2015, 11, 1.	0.8	603
13	Earliest accumulation of Î²-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	12.8	596
14	Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology, 2012, 72, 578-586.	5.3	559
15	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.8	535
16	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 2007, 130, 2616-2635.	7.6	508
17	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
18	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain, 2017, 140, 3286-3300.	7.6	472

#	Article	IF	Citations
19	The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's and Dementia, 2010, 6, 221-229.	0.8	464
20	Anatomical Mapping of White Matter Hyperintensities (WMH). Stroke, 2005, 36, 50-55.	2.0	459
21	Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. Annals of Neurology, 2008, 64, 388-401.	5.3	434
22	Prefrontal atrophy, disrupted NREM slow waves and impaired hippocampal-dependent memory in aging. Nature Neuroscience, 2013, 16, 357-364.	14.8	434
23	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.8	432
24	β-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nature Neuroscience, 2015, 18, 1051-1057.	14.8	411
25	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. Alzheimer's and Dementia, 2010, 6, 239-246.	0.8	402
26	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	7.6	397
27	Imaging the evolution and pathophysiology of Alzheimer disease. Nature Reviews Neuroscience, 2018, 19, 687-700.	10.2	372
28	Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. Journal of Nuclear Medicine, 2013, 54, 70-77.	5.0	364
29	Prevalence of Dementia in Older Latinos: The Influence of Type 2 Diabetes Mellitus, Stroke and Genetic Factors. Journal of the American Geriatrics Society, 2003, 51, 169-177.	2.6	356
30	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 2020, 12, .	12.4	353
31	Old Brains Come Uncoupled in Sleep: Slow Wave-Spindle Synchrony, Brain Atrophy, and Forgetting. Neuron, 2018, 97, 221-230.e4.	8.1	343
32	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 2017, 157, 448-463.	4.2	341
33	Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‑amyloid. Annals of Neurology, 2013, 74, 826-836.	5.3	320
34	Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?. Trends in Neurosciences, 2016, 39, 552-566.	8.6	320
35	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	7.6	319
36	Striatal Dopamine Predicts Outcome-Specific Reversal Learning and Its Sensitivity to Dopaminergic Drug Administration. Journal of Neuroscience, 2009, 29, 1538-1543.	3.6	315

#	ARTICLE	IF	CITATIONS
37	Relationships between Beta-Amyloid and Functional Connectivity in Different Components of the Default Mode Network in Aging. Cerebral Cortex, 2011, 21, 2399-2407.	2.9	306
38	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.8	302
39	Vulnerable Neural Systems and the Borderland of Brain Aging and Neurodegeneration. Neuron, 2013, 77, 219-234.	8.1	285
40	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. Nature Communications, 2020, 11, 2612.	12.8	283
41	Neuropathological basis of magnetic resonance images in aging and dementia. Annals of Neurology, 2008, 63, 72-80.	5.3	282
42	Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain, 2013, 136, 844-858.	7.6	280
43	Association of Lifetime Cognitive Engagement and Low β-Amyloid Deposition. Archives of Neurology, 2012, 69, 623.	4.5	278
44	Measurement of Longitudinal β-Amyloid Change with ^{18}F-Florbetapir PET and Standardized Uptake Value Ratios. Journal of Nuclear Medicine, 2015, 56, 567-574.	5.0	273
45	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.8	266
46	Neuropathologic Substrates of Ischemic Vascular Dementia. Journal of Neuropathology and Experimental Neurology, 2000, 59, 931-945.	1.7	265
47	Working Memory Capacity Predicts Dopamine Synthesis Capacity in the Human Striatum. Journal of Neuroscience, 2008, 28, 1208-1212.	3.6	264
48	Subjective Cognition and Amyloid Deposition Imaging. Archives of Neurology, 2012, 69, 223.	4.5	261
49	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.8	261
50	Anosognosia in Alzheimer's disease: Relationships to depression, cognitive function, and cerebral perfusion. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1993, 15, 231-244.	1.1	258
51	Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). NeuroImage, 2009, 45, 1107-1116.	4.2	258
52	Central Obesity and the Aging Brain. Archives of Neurology, 2005, 62, 1545-8.	4.5	254
53	Striatal Dopamine and Working Memory. Cerebral Cortex, 2009, 19, 445-454.	2.9	251
54	Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain, 2007, 130, 731-739.	7.6	242

#	Article	IF	Citations
55	Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain, 2010, 133, 512-528.	7.6	242
56	Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Annals of Neurology, 2006, 60, 677-687.	5.3	236
57	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	9.0	235
58	Suspected non-Alzheimer disease pathophysiology â€" concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	10.1	230
59	Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Annals of Neurology, 2006, 59, 673-681.	5.3	220
60	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.8	213
61	Considerations and code for partial volume correcting [18 F]-AV-1451 tau PET data. Data in Brief, 2017, 15, 648-657.	1.0	204
62	Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis. JAMA Neurology, 2014, 71, 195.	9.0	201
63	Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. Journal of Neuroscience, 2018, 38, 530-543.	3.6	201
64	Independent information from cerebrospinal fluid amyloid-Î² and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	7.6	200
65	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer's and Dementia, 2015, 11, 757-771.	0.8	199
66	Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Annals of Neurology, 2019, 85, 229-240.	5.3	198
67	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	3.6	196
68	White Matter Changes Compromise Prefrontal Cortex Function in Healthy Elderly Individuals. Journal of Cognitive Neuroscience, 2006, 18, 418-429.	2.3	195
69	Lifespan brain activity, Î²-amyloid, and Alzheimer's disease. Trends in Cognitive Sciences, 2011, 15, 520-526.	7.8	186
70	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.8	181
71	Neural compensation in older people with brain amyloid-Î² deposition. Nature Neuroscience, 2014, 17, 1316-1318.	14.8	167
72	Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spinâ€‹labeling magnetic resonance imaging. Alzheimer's and Dementia, 2009, 5, 454-462.	0.8	163

#	Article	IF	Citations
73	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	2.2	163
74	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.8	162
75	Sleep as a Potential Biomarker of Tau and Î²-Amyloid Burden in the Human Brain. Journal of Neuroscience, 2019, 39, 6315-6324.	3.6	160
76	<i>APOE</i> effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.8	157
77	Multisite study of the relationships between <i>antemortem</i> [¹¹C]PIBâ€PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
78	Longitudinal Change of Biomarkers in Cognitive Decline. Archives of Neurology, 2011, 68, 1257.	4.5	152
79	Factors affecting AÎ² plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 2011, 122, 401-13.	7.7	151
80	Association of brain amyloid-Î² with cerebral perfusion and structure in Alzheimerâ€™s disease and mild cognitive impairment. Brain, 2014, 137, 1550-1561.	7.6	150
81	¹⁸Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	5.3	148
82	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
83	Apolipoprotein E, Not Fibrillar Î²-Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging. Journal of Neuroscience, 2012, 32, 18227-18233.	3.6	146
84	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
85	Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage, 2010, 51, 654-664.	4.2	145
86	Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage, 2011, 56, 52-60.	4.2	144
87	Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. JAMA Neurology, 2013, 70, 1512-9.	9.0	139
88	Vascular burden and Alzheimer disease pathologic progression. Neurology, 2012, 79, 1349-1355.	1.1	138
89	Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. NeuroImage, 2012, 59, 1152-1160.	4.2	137
90	Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not Î²-Amyloid in Cognitively Normal Older Individuals. Journal of Neuroscience, 2013, 33, 5553-5563.	3.6	133

#	Article	IF	Citations
91	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
92	Alzheimer's pathology targets distinct memory networks in the ageing brain. Brain, 2019, 142, 2492-2509.	7.6	131
93	Aβ Deposition in Aging Is Associated with Increases in Brain Activation during Successful Memory Encoding. Cerebral Cortex, 2012, 22, 1813-1823.	2.9	126
94	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience, 2013, 5, 11.	3.4	126
95	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage: Clinical, 2018, 17, 452-464.	2.7	126
96	Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Annals of Neurology, 2015, 77, 338-342.	5.3	124
97	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 215-225.	3.1	122
98	Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region. Journal of Nuclear Medicine, 2015, 56, 560-566.	5.0	122
99	18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research and Therapy, 2019, 11, 13.	6.2	121
100	Dopamine Supports Coupling of Attention-Related Networks. Journal of Neuroscience, 2012, 32, 9582-9587.	3.6	118
101	Impaired Prefrontal Sleep Spindle Regulation of Hippocampal-Dependent Learning in Older Adults. Cerebral Cortex, 2014, 24, 3301-3309.	2.9	117
102	GWAS of longitudinal amyloid accumulation on ^{18}F-florbetapir PET in Alzheimer's disease implicates microglial activation gene *IL1RAP*. Brain, 2015, 138, 3076-3088.	7.6	117
103	Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility. Journal of Neuroscience, 2016, 36, 12559-12569.	3.6	116
104	Memory decline accompanies subthreshold amyloid accumulation. Neurology, 2018, 90, e1452-e1460.	1.1	116
105	Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 483-489.	0.8	113
106	The Aging Brain and Cognition. JAMA Neurology, 2013, 70, 488.	9.0	113
107	Associations between [[18] F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.1	113
108	Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiology of Aging, 2012, 33, 1006.e25-1006.e36.	3.1	112

#	ARTICLE	IF	CITATIONS
109	Tau and Î²-Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging. Journal of Neuroscience, 2017, 37, 3192-3201.	3.6	110
110	Sleep Disturbance Forecasts Î²-Amyloid Accumulation across Subsequent Years. Current Biology, 2020, 30, 4291-4298.e3.	3.9	110
111	Brain imaging in the study of Alzheimer's disease. NeuroImage, 2012, 61, 505-516.	4.2	109
112	White Matter Changes Compromise Prefrontal Cortex Function in Healthy Elderly Individuals. Journal of Cognitive Neuroscience, 2006, 18, 418-429.	2.3	108
113	Gene-Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden. Journal of Neuroscience, 2014, 34, 8612-8617.	3.6	107
114	Mental Status as a Predictor of Daily Function in Progressive Dementia. Gerontologist, The, 1989, 29, 804-807.	3.9	106
115	Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11606-11611.	7.1	105
116	White matter lesions are associated with cortical atrophy more than entorhinal and hippocampal atrophy. Neurobiology of Aging, 2005, 26, 553-559.	3.1	104
117	Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology, 2016, 86, 1377-1385.	1.1	103
118	Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. Neurobiology of Aging, 2014, 35, 1873-1882.	3.1	102
119	Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain, 2015, 138, 3734-3746.	7.6	101
120	Subthreshold Amyloid Predicts Tau Deposition in Aging. Journal of Neuroscience, 2018, 38, 4482-4489.	3.6	101
121	18F-flortaucipir PET to autopsy comparisons in Alzheimerâ€™s disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	7.6	100
122	Î²-Amyloid affects frontal and posterior brain networks in normal aging. NeuroImage, 2011, 54, 1887-1895.	4.2	98
123	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimer's and Dementia, 2015, 11, 1050-1068.	0.8	98
124	Spatial patterns of brain amyloid-Â burden and atrophy rate associations in mild cognitive impairment. Brain, 2011, 134, 1077-1088.	7.6	97
125	Increased Striatal Dopamine Synthesis Capacity in Gambling Addiction. Biological Psychiatry, 2018, 83, 1036-1043.	1.3	97
126	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97

#	ARTICLE	IF	CITATIONS
127	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	3.7	96
128	Effect of Off-Target Binding on ^{18}F-Flortaucipir Variability in Healthy Controls Across the Life Span. Journal of Nuclear Medicine, 2019, 60, 1444-1451.	5.0	96
129	Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's Research and Therapy, 2020, 12, 49.	6.2	96
130	Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline. ELife, 2017, 6, .	6.0	95
131	Effects of Subcortical Cerebral Infarction on Cortical Glucose Metabolism and Cognitive Function. Archives of Neurology, 1999, 56, 809.	4.5	94
132	Reference Tissue–Based Kinetic Evaluation of ^{18}F-AV-1451 for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 332-338.	5.0	94
133	Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals. Brain, 2017, 140, 1499-1512.	7.6	93
134	CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects. Cerebral Cortex, 2012, 22, 1993-2004.	2.9	92
135	Reduced temporal lobe blood flow in alzheimer's disease. Neurobiology of Aging, 1992, 13, 483-491.	3.1	89
136	Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Human Brain Mapping, 2014, 35, 297-308.	3.6	88
137	Relationship of Striatal Dopamine Synthesis Capacity to Age and Cognition. Journal of Neuroscience, 2008, 28, 14320-14328.	3.6	87
138	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	9.0	87
139	Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain, 2016, 139, 23-30.	7.6	87
140	Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability. Cerebral Cortex, 2016, 26, bhu259.	2.9	85
141	Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351. PLoS ONE, 2016, 11, e0158460.	2.5	85
142	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ^{18}F-AV1451 Positron Emission Tomography Imaging. JAMA Neurology, 2018, 75, 999.	9.0	85
143	Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions. Neurology, 2014, 83, 40-47.	1.1	83
144	Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. ELife, 2019, 8, .	6.0	83

#	Article	IF	Citations
145	Clinical Studies of Cerebral Blood Flow in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1997, 826, 254-262.	3.8	82
146	Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with ^{18}F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	5.0	79
147	Performance of patients with early HIV-1 infection on the stroop task. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1992, 14, 857-868.	1.1	78
148	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. Advances in Pharmacology, 2012, 64, 27-81.	2.0	78
149	Associations between White Matter Hyperintensities and Î² Amyloid on Integrity of Projection, Association, and Limbic Fiber Tracts Measured with Diffusion Tensor MRI. PLoS ONE, 2013, 8, e65175.	2.5	77
150	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathologica Communications, 2014, 2, 26.	5.2	77
151	Frontotemporal dementia with the V337M *MAPT* mutation. Neurology, 2017, 88, 758-766.	1.1	76
152	Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurology, 2018, 75, 342.	9.0	76
153	Dynamic relationships between age, amyloid-Î² deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. Brain, 2016, 139, 2275-2289.	7.6	75
154	Brain function and cognition in a community sample of elderly Latinos. Neurology, 2002, 59, 378-383.	1.1	73
155	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	2.7	73
156	Association of *APOE4* and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology, 2021, 96, e650-e661.	1.1	73
157	Early ^{11}C-PIB Frames and ^{18}F-FDG PET Measures Are Comparable: A Study Validated in a Cohort of AD and FTLD Patients. Journal of Nuclear Medicine, 2011, 52, 173-179.	5.0	72
158	Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer's disease variants. Neurobiology of Aging, 2015, 36, 2678-2686.	3.1	72
159	Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. JAMA Neurology, 2016, 73, 1208.	9.0	72
160	Effect of Cognitive Reserve Markers on Alzheimer Pathologic Progression. Alzheimer Disease and Associated Disorders, 2013, 27, 343-350.	1.3	67
161	Amyloid and tau PET demonstrate region-specific associations in normal older people. NeuroImage, 2017, 150, 191-199.	4.2	67
162	Tau deposition is associated with functional isolation of the hippocampus in aging. Nature Communications, 2019, 10, 4900.	12.8	67

#	Article	IF	Citations
163	Coronary risk correlates with cerebral amyloid deposition. Neurobiology of Aging, 2012, 33, 1979-1987.	3.1	66
164	Spontaneous eye blink rate and dopamine synthesis capacity: preliminary evidence for an absence of positive correlation. European Journal of Neuroscience, 2018, 47, 1081-1086.	2.6	66
165	Dopamine and frontostriatal networks in cognitive aging. Neurobiology of Aging, 2012, 33, 623.e15-623.e24.	3.1	65
166	Visuoconstructive performance and regional cerebral glucose metabolism in alzheimer's disease. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1991, 13, 752-772.	1.1	64
167	Brain morphology, cognition, and Î²-amyloid in older adults with superior memory performance. Neurobiology of Aging, 2018, 67, 162-170.	3.1	63
168	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 281.	2.8	62
169	Relationships Between Tau and Glucose Metabolism Reflect Alzheimerâ€™s Disease Pathology in Cognitively Normal Older Adults. Cerebral Cortex, 2019, 29, 1997-2009.	2.9	61
170	The effect of amyloid Î² on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimer's and Dementia, 2013, 9, 687.	0.8	59
171	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. NeuroImage: Clinical, 2014, 4, 508-516.	2.7	59
172	Neurophysiological signatures in Alzheimerâ€™s disease are distinctly associated with TAU, amyloid-Î² accumulation, and cognitive decline. Science Translational Medicine, 2020, 12, .	12.4	59
173	Molecular neuroimaging in Alzheimerâ€™s disease. NeuroRx, 2004, 1, 206-212.	6.0	58
174	Frontotemporal Network Connectivity during Memory Encoding Is Increased with Aging and Disrupted by Beta-Amyloid. Journal of Neuroscience, 2013, 33, 18425-18437.	3.6	58
175	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
176	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	7.6	58
177	Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. JAMA Neurology, 2015, 72, 1183.	9.0	57
178	Associations Between Tau, Î²-Amyloid, and Cognition in Parkinson Disease. JAMA Neurology, 2018, 75, 227.	9.0	57
179	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.8	56
180	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55

#	Article	IF	Citations
181	Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease. Human Brain Mapping, 2016, 37, 4234-4247.	3.6	55
182	Dissociable Effects of Alzheimer Disease and White Matter Hyperintensities on Brain Metabolism. JAMA Neurology, 2013, 70, 1039.	9.0	54
183	Temporal Dynamics of Î²-Amyloid Accumulation in Aging and Alzheimer Disease. Neurology, 2021, 96, e1347-e1357.	1.1	54
184	Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia. , 2006, 2, 36-42.		53
185	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiology of Aging, 2016, 48, 122-134.	3.1	53
186	Subjective cognitive decline and Î²-amyloid burden predict cognitive change in healthy elderly. Neurology, 2017, 89, 2002-2009.	1.1	53
187	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. NeuroImage: Clinical, 2019, 24, 102025.	2.7	53
188	Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology, 2020, 94, e1512-e1524.	1.1	53
189	Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimer's Research and Therapy, 2021, 13, 99.	6.2	53
190	Striatal Dopamine Influences the Default Mode Network to Affect Shifting between Object Features. Journal of Cognitive Neuroscience, 2012, 24, 1960-1970.	2.3	52
191	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.8	51
192	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2014, 10, S226-35.	0.8	51
193	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimerâ€™s disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	6.4	51
194	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	3.3	51
195	Correlations of striatal dopamine synthesis with default network deactivations during working memory in younger adults. Human Brain Mapping, 2011, 32, 947-961.	3.6	50
196	Regional correlations between [11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage: Clinical, 2017, 13, 130-137.	2.7	50
197	White matter integrity and cortical metabolic associations in aging and dementia. , 2010, 6, 54-62.		49
198	Associations Among Vascular Risk Factors, Carotid Atherosclerosis, and Cortical Volume and Thickness in Older Adults. Stroke, 2012, 43, 2865-2870.	2.0	48

#	Article	IF	Citations
199	Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease. NeuroImage: Clinical, 2020, 26, 102199.	2.7	48
200	Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. Biological Psychiatry, 2021, 89, 786-794.	1.3	48
201	Automated template-based PET region of interest analyses in the aging brain. NeuroImage, 2007, 34, 608-617.	4.2	47
202	Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging and Behavior, 2012, 6, 1-15.	2.1	47
203	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 266-273.	1.9	47
204	CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging and Behavior, 2012, 6, 599-609.	2.1	46
205	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease. ELife, 0, 11, .	6.0	45
206	Brain structure and function as mediators of the effects of amyloid on memory. Neurology, 2015, 84, 1136-1144.	1.1	44
207	Association of plasma and cortical amyloid beta is modulated by *APOE* ε4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.8	43
208	Dopamine Synthesis Capacity is Associated with D2/3 Receptor Binding but Not Dopamine Release. Neuropsychopharmacology, 2018, 43, 1201-1211.	5.4	43
209	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Brain, 2022, 145, 713-728.	7.6	43
210	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. Nature Communications, 2021, 12, 5346.	12.8	43
211	Method to correlate1H MRSI and18FDG-PET. Magnetic Resonance in Medicine, 2000, 43, 244-250.	3.0	42
212	Effects of age and β-amyloid on cognitive changes in normal elderly people. Neurobiology of Aging, 2012, 33, 2746-2755.	3.1	42
213	Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	9.0	42
214	Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.1	42
215	Diagnostic utility of ASL–MRI and FDG–PET in the behavioral variant of FTD and AD. Annals of Clinical and Translational Neurology, 2016, 3, 740-751.	3.7	42
216	White Matter Structure in Older Adults Moderates the Benefit of Sleep Spindles on Motor Memory Consolidation. Journal of Neuroscience, 2017, 37, 11675-11687.	3.6	42

#	ARTICLE	IF	CITATIONS
217	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	6.2	42
218	Cognitive and Anatomic Contributions of Metabolic Decline in Alzheimer Disease and Cerebrovascular Disease. Archives of Neurology, 2008, 65, 650-5.	4.5	41
219	Association Between Common Variants in <i>RBFOX1</i>, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. JAMA Neurology, 2020, 77, 1288.	9.0	41
220	Brain perfusion imaging predicts survival in Alzheimer's disease. Neurology, 1998, 51, 1009-1013.	1.1	40
221	What Can Imaging Reveal about Obesity and the Brain?. Current Alzheimer Research, 2007, 4, 135-139.	1.4	40
222	Modulation of impulsivity and reward sensitivity in intertemporal choice by striatal and midbrain dopamine synthesis in healthy adults. Journal of Neurophysiology, 2016, 115, 1146-1156.	1.8	40
223	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.1	39
224	The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. NeuroImage, 2015, 105, 357-368.	4.2	38
225	Elevated ¹⁸ F-AV-1451 PET tracer uptake detected in incidental imaging findings. Neurology, 2017, 88, 1095-1097.	1.1	38
226	Is Verbal Episodic Memory in Elderly with Amyloid Deposits Preserved Through Altered Neuronal Function?. Cerebral Cortex, 2014, 24, 2210-2218.	2.9	36
227	Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology, 2015, 84, 729-737.	1.1	36
228	Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety. Journal of Neuroscience, 2019, 39, 2735-2744.	3.6	36
229	Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum. Neurodegenerative Diseases, 2016, 16, 87-94.	1.4	35
230	Distinct effects of betaâ€amyloid and tau on cortical thickness in cognitively healthy older adults. Alzheimer's and Dementia, 2021, 17, 1085-1096.	0.8	34
231	Diagnostic Accuracy of Amyloid versus ¹⁸Fâ€Fluorodeoxyglucose Positron Emission Tomography in <scp>Autopsyâ€Confirmed</scp> Dementia. Annals of Neurology, 2021, 89, 389-401.	5.3	34
232	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimerâ€™s Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	2.9	34
233	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	10.8	33
234	Speed of memory scanning is not affected in early HIV-1 infection. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1993, 15, 311-320.	1.1	32

#	Article	IF	Citations
235	Genetic effects on behavior are mediated by neurotransmitters and large-scale neural networks. NeuroImage, 2013, 66, 203-214.	4.2	32
236	Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology, 2020, 95, e2075-e2085.	1.1	31
237	Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 97.	6.2	31
238	Correlates of memory function in community-dwelling elderly: The importance of white matter hyperintensities. Journal of the International Neuropsychological Society, 2004, 10, 371-81.	1.8	30
239	Metabolic brain networks in aging and preclinical Alzheimer's disease. NeuroImage: Clinical, 2018, 17, 987-999.	2.7	29
240	Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. Journal of Neuroscience, 2021, 41, 366-375.	3.6	29
241	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. Nature Communications, 2021, 12, 3825.	12.8	29
242	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	9.0	29
243	β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals. Neurobiology of Aging, 2016, 40, 173-180.	3.1	27
244	The Influence of Dopamine on Cognitive Flexibility Is Mediated by Functional Connectivity in Young but Not Older Adults. Journal of Cognitive Neuroscience, 2018, 30, 1330-1344.	2.3	27
245	Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. Neurology, 2020, 95, e2622-e2634.	1.1	27
246	Associations among locus coeruleus catecholamines, tau pathology, and memory in aging. Neuropsychopharmacology, 2022, 47, 1106-1113.	5.4	27
247	Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimer's Disease and Vascular Brain Injury. Journal of Alzheimer's Disease, 2019, 68, 187-196.	2.6	25
248	IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-7.	2.7	25
249	Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction. Frontiers in Human Neuroscience, 2014, 8, 921.	2.0	24
250	Alzheimer Disease Signature Neurodegeneration and *APOE* Genotype in Mild Cognitive Impairment With Suspected Non–Alzheimer Disease Pathophysiology. JAMA Neurology, 2017, 74, 650.	9.0	24
251	Alzheimer's Pathology Is Associated with Dedifferentiation of Intrinsic Functional Memory Networks in Aging. Cerebral Cortex, 2021, 31, 4781-4793.	2.9	24
252	Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Current Alzheimer Research, 2013, 10, 48-56.	1.4	24

#	ARTICLE	IF	CITATIONS
253	Mapping brain Î²-amyloid. Current Opinion in Neurology, 2009, 22, 356-361.	3.6	23
254	Impact of lifestyle dimensions on brain pathology and cognition. Neurobiology of Aging, 2016, 40, 164-172.	3.1	23
255	â€œAlzheimer's diseaseâ€•is neither â€œAlzheimer's clinical syndromeâ€•nor â€œdementiaâ€• Alzheimer's and Dementia, 2019, 15, 153-157.	0.8	23
256	Staging tau pathology with tau PET in Alzheimerâ€™s disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	4.8	23
257	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNIâ€‘3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12226.	3.7	23
258	Abnormal tau in amyloid PET negative individuals. Neurobiology of Aging, 2022, 109, 125-134.	3.1	22
259	The Receiver Operational Characteristic for Binary Classification with Multiple Indices and Its Application to the Neuroimaging Study of Alzheimer's Disease. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2013, 10, 173-180.	3.0	20
260	What are the threats to successful brain and cognitive aging?. Neurobiology of Aging, 2019, 83, 130-134.	3.1	20
261	Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2155-2164.	6.4	20
262	Autosomal dominant and sporadic late onset Alzheimer's disease share a common *in vivo* pathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
263	SPECT Perfusion Imaging in the Diagnosis of Dementia. Journal of Neuroimaging, 1995, 5, S45-52.	2.0	19
264	Dorsal Striatal Dopamine, Food Preference and Health Perception in Humans. PLoS ONE, 2014, 9, e96319.	2.5	19
265	Tauâ€‘Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	5.3	19
266	Physical Activity and AD-Related Pathologyâ€"Reply. Archives of Neurology, 2012, 69, 940.	4.5	17
267	Development of a mnemonic discrimination task using naturalistic stimuli with applications to aging and preclinical Alzheimer's disease. Learning and Memory, 2019, 26, 219-228.	1.3	17
268	Age-related variability in decision-making: Insights from neurochemistry. Cognitive, Affective and Behavioral Neuroscience, 2019, 19, 415-434.	2.0	17
269	Evaluation of a visual interpretation method for tauâ€‘PET with [18] Fâ€‘flortaucipir. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12133.	2.4	17
270	Tau and Î²-Amyloid Burden Predict Actigraphy-Measured and Self-Reported Impairment and Misperception of Human Sleep. Journal of Neuroscience, 2021, 41, 7687-7696.	3.6	17

#	Article	IF	Citations
271	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.8	17
272	Reduced Repetition Suppression in Aging is Driven by Tau–Related Hyperactivity in Medial Temporal Lobe. Journal of Neuroscience, 2021, 41, 3917-3931.	3.6	16
273	A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation. Nature Communications, 2022, 13, 1887.	12.8	16
274	The Complexity of Subjective Cognitive Decline. JAMA Neurology, 2017, 74, 1400.	9.0	15
275	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC–MS/MS Reference Method. Clinical Chemistry, 2020, 66, 587-597.	3.2	15
276	Evaluation of [^{18}F]-JNJ-64326067-AAA tau PET tracer in humans. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3302-3313.	4.3	15
277	Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults. Alzheimer's Research and Therapy, 2021, 13, 174.	6.2	15
278	Genotype status of the dopamine-related catechol-O-methyltransferase (COMT) gene corresponds with desirability of "unhealthy" foods. Appetite, 2015, 92, 74-80.	3.7	14
279	Early life sets the stage for aging. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9148-9150.	7.1	14
280	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Disease and Associated Disorders, 2015, 29, 101-109.	1.3	14
281	Visit-to-Visit Blood Pressure Variability and Longitudinal Tau Accumulation in Older Adults. Hypertension, 2022, 79, 629-637.	2.7	14
282	Amyloid + Activation = Alzheimer's?. Neuron, 2009, 63, 141-143.	8.1	13
283	Plasma Acetylcholinesterase Activity Correlates with Intracerebral β-Amyloid Load. Current Alzheimer Research, 2013, 10, 48-56.	1.4	13
284	Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding. Neurology: Genetics, 2015, 1, e22.	1.9	12
285	Amyloid in dementia associated with familial FTLD: not an innocent bystander. Neurocase, 2016, 22, 76-83.	0.6	12
286	Elevated Dopamine Synthesis as a Mechanism of Cognitive Resilience in Aging. Cerebral Cortex, 2022, 32, 2762-2772.	2.9	12
287	Hippocampal Connectivity with Retrosplenial Cortex is Linked to Neocortical Tau Accumulation and Memory Function. Journal of Neuroscience, 2021, 41, 8839-8847.	3.6	12
288	Single–Photon Emission Computed Tomography Studies of Regional Cerebral Blood Flow in Multiple Infarct Dementia. Journal of Neuroimaging, 1992, 2, 79-85.	2.0	11

#	Article	IF	Citations
289	Time for tau. Brain, 2014, 137, 1570-1571.	7.6	11
290	Tract-Specific Correlates of Neuropsychological Deficits in Patients with Subcortical Vascular Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 50, 1125-1135.	2.6	11
291	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. Nature Communications, 2022, 13, 1495.	12.8	11
292	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	6.4	10
293	Differences in Prefrontal, Limbic, and White Matter Lesion Volumes According to Cognitive Status in Elderly Patients with First-Onset Subsyndromal Depression. PLoS ONE, 2014, 9, e87747.	2.5	10
294	Single-Photon Emission Computed Tomographic Perfusion Imaging in Autopsy-Diagnosed Dementia. Journal of Neuroimaging, 1993, 3, 93-99.	2.0	9
295	Crossed cerebellar diaschisis on ^{18}F-FDG PET: Frequency across neurodegenerative syndromes and association with ^{11}C-PIB and ^{18}F-Flortaucipir. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2329-2343.	4.3	9
296	Relative contributions of biomarkers in Alzheimer's disease. Annals of Epidemiology, 2012, 22, 868-875.	1.9	8
297	Dementia: finding the signals in the noise. Lancet Neurology, The, 2005, 4, 10-11.	10.2	7
298	Following the pathway to Alzheimer's disease. Nature Neuroscience, 2018, 21, 306-308.	14.8	7
299	The changing definition of Alzheimer's disease. Lancet Neurology, The, 2021, 20, 414-415.	10.2	7
300	Conscientiousness is associated with less amyloid deposition in cognitively normal aging.. Psychology and Aging, 2020, 35, 993-999.	1.6	7
301	Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. Nature Aging, 2022, 2, 125-139.	11.6	7
302	Distinct Factors Drive the Spatiotemporal Progression of Tau Pathology in Older Adults. Journal of Neuroscience, 2022, 42, 1352-1361.	3.6	7
303	Quantification of amyloid beta and tau PET without a structural MRI. Alzheimer's and Dementia, 2023, 19, 444-455.	0.8	7
304	Apolipoprotein E, Neurodegeneration, and Alzheimer Disease. JAMA Neurology, 2013, 70, 299.	9.0	6
305	Imaging Tau Pathology—The Next Step. JAMA Neurology, 2020, 77, 796.	9.0	6
306	Multiplex Mass Spectrometry Analysis of Amyloid Proteins in Human Plasma for Alzheimer's Disease Diagnosis. Journal of Proteome Research, 2021, 20, 4106-4112.	3.7	6

#	ARTICLE	IF	CITATIONS
307	Genes and cognitive aging. Frontiers in Neuroscience, 2009, 3, 161-163.	2.8	5
308	A New Tool for Clinical Neuroscience—Synaptic Imaging. JAMA Neurology, 2018, 75, 1181.	9.0	5
309	Head injury is associated with tau deposition on PET in MCI and AD patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12230.	2.4	5
310	Alzheimer Disease Spectrum. Neurology, 2021, 96, 299-300.	1.1	5
311	Biomarkers and Brain Connectivity. JAMA Neurology, 2013, 70, 1233-4.	9.0	4
312	Spatially Adaptive Varying Correlation Analysis for Multimodal Neuroimaging Data. IEEE Transactions on Medical Imaging, 2019, 38, 113-123.	8.9	4
313	Scan-Time Corrections for 80—100-min Standardizetd Uptake Volume Ratios to Measure the ^{18}F-AV-1451 Tracer for Tau Imaging. IEEE Transactions on Medical Imaging, 2019, 38, 697-709.	8.9	4
314	Fusiform gyrus phospho–tau is associated with failure of proper name retrieval in aging. Annals of Neurology, 2021, 90, 988-993.	5.3	4
315	Rates of Î²-amyloid deposition indicate widespread simultaneous accumulation throughout the brain. Neurobiology of Aging, 2022, 115, 1-11.	3.1	4
316	Tracking brain amyloid-Î² in presymptomatic Alzheimer's disease. Lancet Neurology, The, 2012, 11, 1018-1020.	10.2	3
317	Tau and Î²-Amyloid—The Malignant Duo. JAMA Neurology, 2016, 73, 1049.	9.0	3
318	Simultaneous Covariance Inference for Multimodal Integrative Analysis. Journal of the American Statistical Association, 2020, 115, 1279-1291.	3.1	3
319	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.. Journal of Clinical Oncology, 2013, 31, 104-104.	1.6	3
320	Metacognition, cortical thickness, and tauopathy in aging. Neurobiology of Aging, 2022, 118, 44-54.	3.1	3
321	Youthfulness begins in youth. Nature Aging, 2021, 1, 239-240.	11.6	2
322	IC-02-03: EXISTING THRESHOLDS FOR PIB POSITIVITY ARE TOO HIGH. , 2014, 10, P4-P5.		1
323	O3-10-02: LIFETIME COGNITIVE ACTIVITY, APOLIPOPROTEIN E GENOTYPE, AND BRAIN BETA-AMYLOID. , 2014, 10, P228-P228.		1
324	Integrating events in the disintegration of Alzheimer's disease. Brain, 2021, 144, 11-14.	7.6	1

#	Article	IF	Citations
325	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.. Journal of Clinical Oncology, 2013, 31, 6619-6619.	1.6	1
326	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.. Journal of Clinical Oncology, 2013, 31, 6620-6620.	1.6	1
327	Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.. Journal of Clinical Oncology, 2013, 31, 105-105.	1.6	1
328	Sequential pathway inference for multimodal neuroimaging analysis. Stat, 2022, 11, e433.	0.4	1
329	Imaging Studies of Aging, Neurodegenerative Disease, and Alcoholism. Alcohol Health and Research World, 1995, 19, 279-286.	0.2	1
330	O1-01-06: COMPARING LIBERAL AND CONSERVATIVE THRESHOLDS FOR AMYLOID PET POSITIVITY IN AUTOPSY-PROVEN CASES. , 2014, 10, P130-P131.		0
331	P3-007: LOSS OF FUNCTIONAL CONNECTIVITY IS GREATER OUTSIDE THE DEFAULT MODE NETWORK IN NON-FAMILIAL EARLY-ONSET AD VARIANTS. , 2014, 10, P628-P629.		0
332	P2-132: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P534-P535.		0
333	IC-01-01: Are low levels of PiB-PET signal clinically significant?. , 2015, 11, P1-P1.		0
334	P3-145: Are low levels of PiB-PET signal clinically significant?. , 2015, 11, P681-P682.		0
335	IC-P-058: Amyloid negativity in clinically diagnosed ADNI Alzheimer's disease and MCI patients. , 2015, 11, P44-P44.		0
336	IC-P-037: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P33-P34.		0
337	O4-01-06: Tau PET with [18 F]AV1451 in non-alzheimer's disease neurodegenerative syndromes. , 2015, 11, P268-P269.		0
338	P1â€253: Diagnostic Accuracy of Amyloidâ€•Versus Fdgâ€Pet in Autopsyâ€Confirmed Dementia. Alzheimer's and Dementia, 2016, 12, P506.	0.8	0
339	P2-162: NREM Slow Wave Activity <1HZ as a Biomarker and Long-Term Predictor of B-Amyloid Burden in Older Adults. , 2016, 12, P676-P677.		0
340	IC-P-055: Centiloid Thresholds for Amyloid Positivity Derived from Autopsy-Proven Cases. , 2016, 12, P45-P46.		0
341	P1â€295: SNAP: Alzheimer's Disease Plus Overlapping Nonâ€Ad Patterns in The Aging Brain?. Alzheimer's and Dementia, 2016, 12, P533.	0.8	0
342	P2â€285: CENTILOID THRESHOLDS FOR AMYLOID POSITIVITY DERIVED FROM AUTOPSYâ€PROVEN CASES. Alzheimer's and Dementia, 2016, 12, P739.	0.8	0

#	Article	IF	Citations
343	F1-03-03: How ad-Specific are ab and TAU Imaging Biomarkers?. , 2016, 12, P166-P167.		0
344	[F4â€"04â€"04]: NEURAL ACTIVITY REVEALED WITH FMRI IS RELATED TO BETAâ€AMYLOID AND TAU DEPOSITION IN HEALTHY AGING. Alzheimer's and Dementia, 2017, 13, P1215.	0.8	0
345	F5â€03â€03: RESISTANCE TO AD OVER THE LIFECOURSE. Alzheimer's and Dementia, 2018, 14, P1629.	0.8	0
346	Tau spreads through episodic memory networks in the aging brain. Alzheimer's and Dementia, 2020, 16, e037502.	0.8	0
347	Molecular neuroimaging in Alzheimerâ€™s disease. Neurotherapeutics, 2004, 1, 206-212.	4.4	0
348	Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer. Journal of Oncology, 2022, 2022, 1-9.	1.3	0